The abstract is read at the publisher; the summary is JClub's.
Sex is increasingly recognized as a biological variable shaping antitumor immune effectiveness and immunotherapy response, with male and female immune responses differing in their effectiveness against tumors.
- Why it matters: Patient response to immunotherapy varies widely, and current stratification efforts have not incorporated sex despite long-standing sex differences in immunobiology.
- What they did: The review synthesizes research over the past decade, including NIH-driven reporting changes for sex as a biological variable, to examine how sex shapes antitumor immunity and treatment responses.
- The result: The accumulated evidence suggests sex-linked differences in antitumor immunity are relevant for immunotherapy outcomes, informing how future patient stratification and care might be approached.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.